Nanomedicine for Tumor Hypoxia Management

Tumour hypoxia arises when oxygen delivery fails to meet the high metabolic demands of proliferating cancer cells, leading to resistance to radiotherapy, chemotherapy, phototherapy and immunotherapy. Nanomedicine seeks to address this challenge by engineering nanoscale systems that either supply oxygen directly, catalyse in situ oxygen generation, conserve existing oxygen or leverage oxygen-independent mechanisms. Strategies include perfluorocarbon-based oxygen carriers, catalytic nanoparticles that decompose endogenous hydrogen peroxide to yield oxygen, oxygen-economising platforms that reduce tumour consumption, and hypoxia-activated therapies that become potent under low oxygen tensions. Beyond therapeutic enhancement, many systems incorporate imaging capabilities—such as chemical exchange saturation transfer or photoacoustic modalities—to monitor oxygen dynamics and guide treatment timing. The interdisciplinary integration of materials science, bioengineering and tumour biology has yielded multifunctional nanoplatforms capable of modulating the tumour microenvironment, improving drug delivery, amplifying reactive oxygen species and stimulating antitumour immunity. Global efforts now focus on optimising biocompatibility, pharmacokinetics, targeted delivery and scalable manufacturing to facilitate clinical translation and broad adoption in oncology.

Research from Nature Portfolio

One novel approach employs glycerol-weighted perfluorocarbon nanoprobes with dual 19F/1H chemical exchange saturation transfer imaging. These probes not only deliver oxygen to hypoxic regions but enable real-time, quantitative visualisation of pH and oxygen levels to define optimal radiotherapy windows. Oxygenated probes significantly alleviate hypoxia, enhancing radiotherapy outcomes with clear MR-based guidance. A second study introduces an organosilica-based nanoeconomiser that conserves endogenous oxygen by releasing nitric oxide in the acidic tumour milieu, while simultaneously providing exogenous oxygen through mild photothermal activation. This two-pronged strategy reduces cellular oxygen demand and broadens oxygen supply, markedly improving radiotherapy efficacy and demonstrating synergistic tumour eradication in vivo. Foundational work with perfluorocarbon nanoparticles has also demonstrated the creation of a long-lasting, penetrable hypoxic microenvironment that enhances accumulation and activation of hypoxia-targeted therapeutics over extended periods, reigniting interest in bioreductive prodrug strategies.

Nanomedicine for Tumor Hypoxia Management publication trend

The graph below shows the total number of articles in nanomedicine for tumor hypoxia management across all publications each year (not limited to Nature Index journals).

Technical terms

Tumour hypoxia: A condition in which insufficient oxygen levels within solid tumours impair cell death pathways and promote treatment resistance.

Nanocarrier: A nanoscale vehicle engineered to transport therapeutic or diagnostic agents to specific tissues or cells.

Perfluorocarbon nanoparticle: A particle composed of fluorinated carbon compounds capable of dissolving and transporting large amounts of oxygen.

Chemical exchange saturation transfer (CEST): An MRI technique that detects exchangeable protons in molecules for quantitative imaging of biochemical environments.

Gas-entrapping materials (GeMs): Porous or encapsulating matrices designed to load and release gases such as oxygen in a controlled manner.

Photodynamic therapy (PDT): A treatment modality that uses light-activated photosensitisers to generate cytotoxic reactive oxygen species in the presence of oxygen.

References

1. Glycerol-weighted chemical exchange saturation transfer nanoprobes allow 19F/1H dual-modality magnetic resonance imaging-guided cancer radiotherapy. Nature Communications (2023).
2. A hybrid semiconducting organosilica-based O2 nanoeconomizer for on-demand synergistic photothermally boosted radiotherapy. Nature Communications (2021).
3. Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy. Nature Communications (2019).
4. Low‐Cost, High‐Pressure‐Synthesized Oxygen‐Entrapping Materials to Improve Treatment of Solid Tumors. Advanced Science (2023).
5. Advances in nanomaterials for treatment of hypoxic tumor. National Science Review (2020).
6. Oxygen-Sufficient Nanoplatform for Chemo-Sonodynamic Therapy of Hypoxic Tumors. Frontiers in Chemistry (2020).